The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. Eli Lilly stock skidded.

Shares of Eli Lilly & Co. LLY shed 6.45% to $738.21 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 5.97% to 5,074.08 and Dow ...

Real-time index price for Nasdaq Composite (NASX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

The Chief Executive of Eli Lilly has told the BBC that he is doubtful tariffs could bring manufacturing jobs to the US whilst ...

Eli Lilly & Co. closed 18.86% short of its 52-week high of $972.53, which the company reached on August 22nd.

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Biogen BIIB announced that the FDA has granted fast track designation to its investigational Alzheimer's disease (AD) drug, ...

Trump announced a 10% tariff on all U.S. trading partners, in addition to higher reciprocal tariffs on the EU and China. But ...

The White House Wednesday listed tariff rates for different countries. It didn’t take long for market observers to try and reverse engineer the formula.

Some of the country's largest drugmakers could be impacted by President Donald Trump's reciprocal tariffs, announced on ...

In a report released today, Steve Scala from TD Cowen maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

The Weight Loss Drugs Market is poised for significant growth from 2025 to 2035. With increasing obesity rates, rising ...